These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29783877)

  • 1. Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?
    Hamzic S; Amstutz U; Largiadèr CR
    Pharmacogenomics; 2018 Jun; 19(8):689-692. PubMed ID: 29783877
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of pharmacogenetics in capecitabine efficacy and toxicity.
    Lam SW; Guchelaar HJ; Boven E
    Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using pharmacogenetics to prevent severe adverse reactions to capecitabine.
    García-González X; López-Fernández LA
    Pharmacogenomics; 2017 Aug; 18(13):1199-1213. PubMed ID: 28746000
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity.
    Pellicer M; García-González X; García MI; Blanco C; García-Alfonso P; Robles L; Grávalos C; Rueda D; Martínez J; Pachón V; Longo F; Martínez V; Iglesias I; Salvador S; Sanjurjo M; López-Fernández LA
    Pharmacogenomics; 2017 Aug; 18(13):1215-1223. PubMed ID: 28745575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
    Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
    Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH
    Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798).
    González-Perera I; Gutiérrez-Nicolás F; Nazco-Casariego GJ; Ramos-Díaz R; Hernández-San Gil R; Pérez-Pérez JA; González García J; González De La Fuente GA
    J Oncol Pharm Pract; 2017 Jul; 23(5):396-398. PubMed ID: 27122156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
    Lunenburg CA; van Staveren MC; Gelderblom H; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2016 May; 17(7):721-9. PubMed ID: 27181275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Letter.
    van Kuilenburg AB; Largiadèr CR
    Clin Cancer Res; 2011 Sep; 17(17):5837; author reply 5835-6. PubMed ID: 21878539
    [No Abstract]   [Full Text] [Related]  

  • 12. SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.
    Opdam FL; Swen JJ; Wessels JA; Gelderblom H
    Clin Cancer Res; 2011 Sep; 17(17):5833-4; author reply 5835-6. PubMed ID: 21878541
    [No Abstract]   [Full Text] [Related]  

  • 13. A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing.
    Glewis S; Alexander M; Khabib MNH; Brennan A; Lazarakis S; Martin J; Tie J; Lingaratnam S; Michael M
    Br J Cancer; 2022 Jul; 127(1):126-136. PubMed ID: 35306539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of new SNPs associated with severe toxicity to capecitabine.
    Pellicer M; García-González X; García MI; Robles L; Grávalos C; García-Alfonso P; Pachón V; Longo F; Martínez V; Blanco C; Iglesias I; Sanjurjo M; López-Fernández LA
    Pharmacol Res; 2017 Jun; 120():133-137. PubMed ID: 28347776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.
    Terrazzino S; Cargnin S; Del Re M; Danesi R; Canonico PL; Genazzani AA
    Pharmacogenomics; 2013 Aug; 14(11):1255-72. PubMed ID: 23930673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
    Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
    PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
    Meulendijks D; Cats A; Beijnen JH; Schellens JH
    Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
    Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
    Cancer; 2017 Jan; 123(2):345-356. PubMed ID: 27622829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.